title: Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
abstract: BACKGROUND
  High-dose therapy (HDT) with stem-cell support is the reference treatment for relapsed lymphoma, but is not appropriate for all patients. Conventional salvage chemotherapies have been used with limited efficacy and significant toxicity. Rituximab, gemcitabine and oxaliplatin are active as single agents in relapsed or refractory lymphoma, and have demonstrated synergistic effects in vitro and in vivo.
  
  
  METHODS
  Forty-six patients with relapsed or refractory B-cell lymphoma received up to eight cycles of R-GemOx (rituximab 375 mg/m(2) on day 1, gemcitabine 1000 mg/m(2) and oxaliplatin 100 mg/m(2) on day 2). The majority (72%) had diffuse large B-cell lymphoma.
  
  
  RESULTS
  After four cycles of R-GemOx, the overall response rate was 83% [50% complete response (CR)/unconfirmed CR (CRu)]. High CR/CRu rates were observed in all histological subtypes. In patients who had previously received rituximab, the CR/CRu rate after eight cycles was 65%. The 2-year event-free and overall survival rates (median follow-up of 28 months) were 43% and 66%, respectively. Among responders, the probability of being disease free for 2 years was 62%. Treatment was generally well tolerated.
  
  
  CONCLUSIONS
  R-GemOx shows promising activity with acceptable toxicity in patients with relapsed/refractory B-cell lymphoma who are not eligible for HDT.
authors.affiliation: Department of Clinical Hematology, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris XII University, Créteil, France.
authors.forename: T
authors.initials: T
authors.lastname: El Gnaoui
authors.forename: J
authors.initials: J
authors.lastname: Dupuis
authors.forename: K
authors.initials: K
authors.lastname: Belhadj
authors.forename: J-P
authors.initials: JP
authors.lastname: Jais
authors.forename: A
authors.initials: A
authors.lastname: Rahmouni
authors.forename: C
authors.initials: C
authors.lastname: Copie-Bergman
authors.forename: I
authors.initials: I
authors.lastname: Gaillard
authors.forename: M
authors.initials: M
authors.lastname: Diviné
authors.forename: I
authors.initials: I
authors.lastname: Tabah-Fisch
authors.forename: F
authors.initials: F
authors.lastname: Reyes
authors.forename: C
authors.initials: C
authors.lastname: Haioun
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069283:Rituximab; D000093542:Gemcitabine